Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSYN 3.5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Off-label: Adjunctive therapy in catabolic states (e.g., burns, trauma, sepsis)
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral/enteral nutrition is impossible or insufficient
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.
Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary.
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Metabolized via amino acid oxidation and gluconeogenesis in the liver and kidneys. Dextrose undergoes glycolysis and oxidative phosphorylation. Electrolytes are not metabolized but excreted or retained as needed.
Amino acids are metabolized primarily in the liver via deamination, transamination, and urea cycle; some metabolism occurs in peripheral tissues.
Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
None for components. Amino acids: minimal (<10%).
Amino acids have minimal protein binding (less than 10%), primarily to albumin, but binding is negligible for pharmacokinetic purposes.
Not applicable as a mixture; individual components distribute into total body water (0.6 L/kg) or extracellular fluid (0.2 L/kg).
Volume of distribution for amino acids is approximately 0.2-0.4 L/kg, reflecting distribution primarily into extracellular fluid and lean tissue compartments. This low Vd indicates limited extravascular distribution.
Intravenous: 100% (only route).
Intravenous: 100% bioavailability. Not applicable to other routes; oral administration is not indicated due to first-pass metabolism and variable absorption.
In renal impairment (GFR <30 m L/min): restrict fluid and electrolytes; use specialized amino acid formulations (e.g., essential amino acid solutions). Dextrose content may cause hyperglycemia; monitor glucose. Reduce volume and electrolytes as needed. For non-dialysis patients, avoid unless specific benefits outweigh risks.
For GFR 30-59 m L/min: reduce dose by 50% and monitor serum BUN. For GFR 15-29 m L/min: reduce dose by 75%. For GFR <15 m L/min: avoid use unless on renal replacement therapy; if used, adjust based on amino acid losses during dialysis.
In hepatic impairment (Child-Pugh class B or C): monitor for encephalopathy; amino acid load may precipitate hepatic encephalopathy. Use lower protein intake (0.6-0.8 g/kg/day) or branched-chain amino acid enriched solutions. Dextrose may exacerbate hyperglycemia; adjust insulin as needed.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor ammonia levels. Child-Pugh Class C: avoid use or use with caution, reduce dose by 75% and monitor for hepatic encephalopathy.
Weight-based: neonates 1-3 g/kg/day amino acids, up to 15 g/kg/day dextrose, titrated. Infants and children: 1-2 g/kg/day amino acids, 10-20% dextrose at 1-2 m L/kg/hour. Adjust electrolytes per serum levels. Use age-specific formulations; monitor growth and metabolic parameters.
Intravenous infusion of 1-2 g amino acids/kg/day (equivalent to 28.6-57.1 m L/kg/day of 3.5% solution). For preterm infants: start at 1 g/kg/day and advance by 0.5 g/kg/day to target 2-3 g/kg/day. Titrate based on serum amino acid profiles and growth parameters.
Elderly: start at lower volume (0.5-1 L/day) due to reduced renal function and fluid reserve. Monitor glucose and electrolytes closely; dextrose load may require insulin. Amino acid dosing per protein requirements (1-1.2 g/kg/day if no renal impairment). Adjust for comorbidities.
No specific dose adjustment based on age alone; however, elderly patients often have reduced renal function and lean body mass. Initiate at lower end of dosing range (e.g., 0.5 g amino acids/kg/day) and titrate slowly, monitoring renal function and fluid status.
Not for intravenous injection as a sole source of nutrition. Contains aluminum that may be toxic. Use with caution in renal impairment due to aluminum accumulation. Do not administer unless solution is clear and container undamaged.
None
Risk of hyperglycemia, especially in diabetic patients,Electrolyte imbalances (hyperkalemia, hypophosphatemia, etc.),Volume overload in patients with heart failure or renal disease,Aluminum toxicity with prolonged use, especially in renal impairment,Thrombophlebitis and infection at infusion site,Refeeding syndrome in malnourished patients
Risk of metabolic acidosis,Hepatic and renal impairment may require dose adjustment,Monitor serum electrolytes, fluid balance, and ammonia levels,Do not administer if solution is cloudy or contains particulates
Anuria or severe renal impairment without appropriate monitoring,Inborn errors of amino acid metabolism (e.g., phenylketonuria),Severe electrolyte disorders before correction,Hyperglycemia uncontrolled by insulin,Hypersensitivity to any component
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hepatic failure or hepatic coma,Severe azotemia or uremia not related to dialysis
None; parenteral nutrition bypasses gastrointestinal tract. However, monitor oral intake if transitioning to enteral nutrition.
No direct food interactions, as this is administered intravenously. However, concurrent oral intake should be avoided until parenteral nutrition is adjusted. Monitor for refeeding syndrome if transitioning to oral nutrition.
No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if clearly needed. Potential fetal risks include metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) associated with maternal administration of dextrose and electrolytes, which may affect fetal homeostasis. However, no specific teratogenic effects have been documented.
Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose risks. During pregnancy, use only if clearly needed due to the risk of electrolyte imbalances, fluid overload, or metabolic disturbances that could affect the fetus. There are no adequate studies in pregnant women. The potential for fetal harm based on animal reproduction studies is not available.
It is not known whether components of this solution are excreted in human milk. No M/P ratio available. Caution should be exercised when administered to a breastfeeding woman. The high dextrose content may affect maternal glucose levels, indirectly influencing milk composition. Consider the benefits of breastfeeding and the importance of the drug to the mother.
It is not known whether amino acids from Aminosyn 3.5% are excreted in human breast milk. The M/P ratio is not established. Caution should be exercised when administered to a nursing woman, as the effect on the breastfed infant is unknown. Consider the benefits of breastfeeding and the mother's need for the drug.
Pharmacokinetic changes in pregnancy may require dose adjustments: increased plasma volume and glomerular filtration rate may alter electrolyte and fluid balance; increased insulin resistance may necessitate modifications in dextrose delivery. Monitor glycemic control and adjust dextrose infusion rate accordingly. Electrolyte requirements may change; adjust based on serum levels. No specific dosing guidelines are established; individualize based on maternal clinical status and laboratory parameters.
Dosing adjustments may be necessary due to increased plasma volume and altered protein metabolism in pregnancy. Increased requirements for certain amino acids (e.g., threonine, lysine) may need to be considered. Monitor nitrogen balance and adjust total amino acid dose based on maternal weight, gestational age, and clinical response. Close monitoring of plasma amino acid levels and metabolic parameters is recommended to avoid excess or deficiency.
Contains 2.75% amino acids, 15% dextrose, and electrolytes. Ensure central line access for high osmolality (approx. 1450 m Osm/L). Monitor serum electrolytes, glucose, and fluid status. Avoid in patients with severe metabolic alkalosis or anuria. Contains sulfite, may cause allergic reactions in asthmatics.
AMINOSYN 3.5% is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, blood urea nitrogen (BUN), and ammonia levels. Do not administer simultaneously with blood products via same infusion line due to risk of incompatibility. Use with caution in patients with hepatic or renal impairment. Central line administration is required for concentrations >5%, but 3.5% can be infused via peripheral vein if adequately diluted and with careful monitoring for thrombophlebitis.
This solution provides nutrition and fluids directly into your vein.,Your blood sugar and electrolyte levels will be monitored regularly.,Report any signs of infection at the IV site like redness, swelling, or warmth.,Do not stop or adjust the infusion rate yourself.
This medication is given intravenously to provide protein when you cannot eat normally.,You may require regular blood tests to monitor kidney and liver function, as well as electrolyte levels.,Report any signs of infection at the IV site, such as redness, swelling, or warmth.,Do not stop or adjust the infusion rate without your healthcare provider's guidance.,Inform your doctor if you have diabetes, liver disease, or kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSYN 3.5%, answered by our medical review team.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.. AMINOSYN 3.5% is a Parenteral Nutrition Solution that works by Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSYN 3.5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is: TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.. The standard adult dose of AMINOSYN 3.5% is: Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSYN 3.5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if. AMINOSYN 3.5% is classified as Category C. Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.